For NSCLC, the overexpression of EZH2 is linked to vascular endothelial growth factor-A (VEGF-A) signaling and correlates with a shorter survival time for patients, as the aggressiveness of the lung cancer cells increases [13]. Here, VEGFA is linked to lung cancer.